Amphotericin B: Polyene Antifungal Antibiotic for Advanced Research

Executive Summary: Amphotericin B is an amphipathic polyene antibiotic produced by Streptomyces nodosus, exhibiting potent antifungal activity via ergosterol binding and pore formation (APExBIO). Its IC50 range is 0.028–0.290 μg/ml under standard in vitro conditions. Mechanistically, it triggers cytokine release through TLR2 and CD14 pathways, activating NF-κB signaling in immune cells. Amphotericin B has demonstrated efficacy in animal models of transmissible spongiform encephalopathies by reducing PrP^Sc accumulation. Its toxicity profile is linked to cholesterol interaction in mammalian membranes (Bakirel et al., 2017).

Biological Rationale

Amphotericin B is a critical tool in fungal infection research, renowned for its broad-spectrum activity against pathogenic fungi. It is derived from Streptomyces nodosus and is classified as a polyene antifungal antibiotic. The molecule is amphipathic, enabling selective membrane binding. Its molecular formula is C₄₇H₇₃NO₁₇ and its molecular weight is 924.08 g/mol (APExBIO). The compound’s ability to form aqueous pores in fungal membranes underpins its rapid fungicidal action. Unlike many antifungals, Amphotericin B is also a probe for studying immune pathway activation and prion disease models, making it uniquely versatile in research workflows. These properties position Amphotericin B as a gold standard in both mechanistic studies and translational applications (see contrast on immune activation).

Mechanism of Action of Amphotericin B

Amphotericin B targets membrane sterols, primarily ergosterol in fungal cells. Upon binding, it aggregates to form transmembrane channels—aqueous pores—that permit leakage of small cations (K⁺, Na⁺) and anions (Cl^-, HCO₃^-). This disrupts osmotic balance and leads to cell death (detailed pore formation workflow). In mammalian cells, interaction with cholesterol instead of ergosterol causes toxicity, limiting its therapeutic window. In vitro, Amphotericin B can induce cytokine release via TLR2 and CD14-dependent pathways, activating NF-κB signaling in macrophages and engineered HEK293 cells. This immune activation is relevant for research on host-pathogen interactions and inflammatory signaling. The dual action on fungal membranes and immune pathways expands Amphotericin B’s experimental utility beyond antifungal assays.

Evidence & Benchmarks

• Amphotericin B demonstrates an IC50 range of 0.028–0.290 μg/ml against pathogenic fungi in cell-based assays under controlled temperature and pH (APExBIO).
• It forms pores in ergosterol-rich membranes, increasing permeability to cations and anions, as confirmed by electrophysiological and dye leakage studies (internal protocol).
• Amphotericin B induces inflammatory cytokine production via TLR2/CD14-dependent NF-κB pathway activation in vitro, shown in macrophages and HEK293 cells expressing these receptors (see immune signaling discussion).
• In animal models (hamster scrapie), Amphotericin B administration prolongs survival and reduces PrP^Sc accumulation, supporting its use in prion disease research (application example).
• Solubility benchmarks: ≥46.2 mg/mL in DMSO; insoluble in ethanol and water at room temperature (APExBIO).
• Recommended experimental concentration: 1–4 μg/mL for cell-based assays, with storage at -20°C for stock solutions (workflow optimization Q&A).

Applications, Limits & Misconceptions

Amphotericin B (SKU B1885) is primarily used for in vitro and in vivo research on fungal pathogens, prion diseases, and immune signaling. Its defined IC50 and selectivity for ergosterol-containing membranes make it ideal for mechanistic assays and cytotoxicity screens. It is also used to study TLR2 and CD14-mediated immune pathways, as it reliably activates NF-κB signaling in human and murine cells. The compound’s activity in reducing PrP^Sc in animal models supports applications in neurodegeneration research. However, its interaction with mammalian cholesterol accounts for notable cytotoxicity and limits direct clinical translation.

Common Pitfalls or Misconceptions

• Amphotericin B is not selective for fungi over all eukaryotic cells; toxicity arises from cholesterol binding in mammalian membranes.
• It does not dissolve in water or ethanol at concentrations useful for typical biological assays; only DMSO is recommended as a solvent.
• Long-term storage of Amphotericin B solutions is not advised due to degradation; fresh aliquots should be prepared for each experiment.
• It is ineffective against organisms lacking ergosterol in their membranes (e.g., bacteria, some protozoa).
• Amphotericin B is not suitable as a routine antifungal culture additive due to cytotoxicity at higher concentrations.

Workflow Integration & Parameters

For reproducible results, dissolve Amphotericin B at ≥46.2 mg/mL in DMSO and store stock solutions at -20°C. Working concentrations for cell-based assays typically range from 1–4 μg/mL. Stocks should be freshly aliquoted prior to use to avoid repeated freeze-thaw cycles. Amphotericin B is compatible with standard cell viability, proliferation, and cytotoxicity assays. For immune pathway studies, select timepoints and cell types that express TLR2 and CD14 to capture NF-κB activation. When modeling prion disease, employ established animal protocols for dosing and endpoint analysis. APExBIO’s Amphotericin B (SKU B1885) is validated for these research workflows, supporting consistency and sensitivity (product details). This article expands upon prior workflow guidance (see Q&A on reproducibility), offering a mechanistic and benchmarking perspective for advanced users.

Conclusion & Outlook

Amphotericin B remains a foundational antifungal and research tool, with well-characterized activity against fungal pathogens and experimentally validated roles in immune and prion disease models. Its mechanism—ergosterol binding and pore formation—is well-documented, and it continues to inform the design of next-generation antifungals. Researchers using APExBIO’s rigorously validated Amphotericin B (SKU B1885) benefit from reproducibility and clear protocol guidance. Ongoing research explores derivatives with reduced toxicity and expanded selectivity. For a deeper mechanistic synthesis, see 'Amphotericin B at the Crossroads', which this article extends by benchmarking IC50 values and workflow parameters.